SCHEMBL2695402

SCHEMBL2695402

CC(C)N(c1ccccc1)S(C)(=O)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.55
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
HSD11B1 P28845 2/20 0.41
LMNA P02545 2/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NR3C2 P08235 1/20 0.40
USP2 O75604 1/20 0.39
PTPN1 P18031 1/20 0.39
CES1 P23141 1/20 0.39
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CA12 O43570 1/20 0.38
CA2 P00918 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7462661 0.82 POLB (0.57) ESR1POLBCYP3A4CYP2D6CYP2C9
SCHEMBL16178528 0.81 ESR1 (0.46) ESR1POLBCYP3A4CYP2D6CYP2C9
SCHEMBL10927434 0.80 ESR1 (0.53) ESR1POLBHSD11B1LMNAALDH1A1
SCHEMBL7470800 0.79 POLB (0.58) ESR1POLBCYP3A4CYP2D6CYP2C9
SCHEMBL2993431 0.78 ALDH1A1 (0.43) ESR1CYP3A4CYP2D6CYP2C9CYP2C19
SCHEMBL5191774 0.78 ESR1 (0.77) ESR1HSD11B1ALDH1A1KMT2ACA12
SCHEMBL1355880 0.78 ESR1 (0.36) ESR1POLBCYP3A4CYP2D6CYP2C9
SCHEMBL6325501 0.78 HSD11B1 (0.47) HSD11B1ALDH1A1TP53SMN1; SMN2CES1
SCHEMBL8224812 0.78 HSD11B1 (0.40) ESR1HSD11B1LMNANR3C2CES1
SCHEMBL4433011 0.77 LMNA (0.41) ESR1POLBCYP3A4NPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8692001-B2 Sulfonamides for the modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2014-04-08 US disclosed
US-8692001-B2 Sulfonamides for the modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2014-04-08 US disclosed
EP-2632920-A1 SULFONAMIDES FOR THE MODULATION OF PKM2 Dynamix Pharmaceuticals Ltd. (IL) 2013-09-04 EP disclosed
WO-2012056319-A1 SULFONAMIDES FOR THE MODULATION OF PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 WO disclosed
WO-2012056319-A1 SULFONAMIDES FOR THE MODULATION OF PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 WO disclosed
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 US disclosed
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 US disclosed
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 DYNAMIX PHARMACEUTICALS LTD. (IL) 2012-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108631-A1 Sulfonamides for the Modulation of PKM2 PDK1, PDK4, PDK2 ESR1 2454/4885POLB 4129/4885CYP3A4 2327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.